Assessment of Some Hematological Parameters in Iraqi Women with Different Breast Cancer Stages

Zahra M. Ali* and Shatha H. Ali* and Forat Y. Mohsen**

*Department of Clinical Laboratory Science, College of Pharmacy, University of Baghdad, Baghdad, Iraq
**Ministry of Health and Environment, Medical City, Oncology Teaching Hospital, Baghdad, Iraq

Abstract

Breast cancer (BC) is the most commonly diagnosed cancer in women. The metabolism of iron is closely regulated by hepcidin which exerts its action by interacting with a ferroportin.

The aim of the present study was to assess the alterations in the levels of some serum biomarkers that have a role in iron homeostasis (hepcidin and ferroportin) in addition to hematological parameters (hemoglobin, leukocyte count and platelets count) in different stages of BC.

This study included 66 women with BC. The patients were categorized as follows: group 1 includes 22 patients with stage I disease, group 2 includes: 22 patients with stage II disease, and group 3 include: 22 patients with stage III disease. Group 4 includes 22 apparently healthy women as control.

Data analysis revealed a significant elevation of serum hepcidin levels of patients groups 1, 2, and 3 (437.2±26.4, 501.4±31.8 and 558.5±21.3 pg/ml respectively) vs (179.4±19.8 pg/ml) of control, with steady elevations from stage I to III.

Furthermore, serum ferroportin levels were significantly lowered in groups 1 and 3 compared to control (0.589±0.107 and 0.733±0.1 vs 1.37±0.28 ng/ml respectively). While blood hemoglobin level of group 3 were lower (11.96±0.18 vs 12.7±0.13g/dl) compared with controls.

Blood leukocyte count for patients in group 2&3 were significantly increased compared to controls (7.39±0.28, 8.93±0.48, 9.86±0.52 (10^3/µl) respectively) were markedly increased compared to controls (313.9±25.3 vs 233.3±49.1 respectively).

In conclusion, hepcidin, ferroportin and hematological markers including hemoglobin, WBC count and platelets count are altered in women with BC compared to healthy control. The changes occur mostly in accordance with disease stages.

Key words: Breast cancer, Hepcidin , Ferroportin.
Introduction

Breast cancer (BC) is the most commonly diagnosed cancer in women, it is estimated to affect (24.2%) of women worldwide. In Iraq, the number of new cases in 2018 for both sexes, and for all age groups was 5141 which represent 20.3% of all new cases for all cancer types (25320), while the number of prevalent cases of all cancer types over 5 years for all ages was 54809 cases (1).

Breast carcinomas is the most common type of BC although different types of sarcomas and lymphomas also can be encountered (2).

Chronic inflammation is a key participant in cancer development and progression (3). The mechanism by which chronic inflammation is related to BC prognosis is not fully clear. However, complex processes through which chronic inflammation may promote carcinogenesis such as polarization of M2 tumor-associated macrophages via inflammatory cytokines with the subsequent production of tumor growth factors or promotion of angiogenesis (4,5). In addition, several prognostic factors are correlated with inflammatory status such as body fatness, physical activity, and cardiovascular comorbidity, which may affect tumor prognosis through alternate mechanisms. Meanwhile, the presence of undetected cancer cells may result in inflammation, thus inflammation may not only contributor to tumor promotion, but also result of these cancer cells (6).

The American Society of Clinical Oncology (ASCO) recommends the use of tumor markers in prevention, screening, treatment and surveillance of BC. The most common clinically applied tumor markers for breast cancer are CA 15-3, CA 27.29, Carcinoembryonic antigen (CEA), Estrogen receptor (ER), Progesterone receptor (PR), Human epidermal growth factor receptor 2 (HER2), urokinase plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1) and multiparameter assays for gene expression (7).

The metabolism of iron is closely regulated by hepcidin which is liver-derived peptide. It exerts its action by interacting with a ferroportin (FPN), a transmembrane protein implicated in iron efflux from the body iron stores (8). Binding of hepcidin with FPN exerts a negative effect on erythropoiesis by inducing internalization and then subsequently destruction of FPN (8,9).

Increased erythropoiesis suppresses hepcidin production, while iron loading and inflammation induce its production. Blood loss, anemia, increased erythropoietin or hypoxia stimulate bone marrow erythropoiesis and then reduce hepcidin (10,11). Increase in serum hepcidin has been reported increasingly from diverse clinical states, (neoplastic diseases, inflammation, and sepsis) (10,12,13). Sideropenic anemia is frequently reported in cancer patients, (14) that is mediated by the inflammatory cytokines produced by cancer cells and by macrophages infiltrating the cancer tissue (15). These cytokines stimulate the hepatic production of hepcidin, which in turn inhibit iron absorption in the duodenum and promote iron sequestration by macrophages limiting its recycling (16). Moreover, the inflammatory cytokines decrease FPN expression in duodenal enterocytes blocking the transport of iron from enterocytes to transferrin (16). IL-10 also induces an increase in serum ferritin and soluble transferrin receptor (sTfR) levels causing anemia (17).

The role of peripheral WBC in predicting incident BC remains to be determined in spite of the established role of peripheral WBCs in BC prognosis (18-19). Many studies showed the lack of association between total white blood cell count (TWBCC) and BC risk (20,21); yet, TWBCC serves as a significant predictor of certain types of BC and for other types of cancer like lung (20), gastric (22), and colorectal cancers (23).

Furthermore, platelets have important roles in various physiological and pathophysiological processes, including inflammation, immunity, angiogenesis, wound healing, and cancer progression (24-25). Platelet dysfunction and thrombotic disorders are important manifestations of cancer progression (24-26). Thrombocytosis is associated with poor cancer prognosis, suggesting a potential role for platelets in the pathogenesis of the disease (27-28).

The aim of the present study was to assess the alterations in the levels of some serum biomarkers that have a role in iron homeostasis (hepcidin and ferroportin) in addition to hematological parameters (hemoglobin, leukocyte and platelets count) in different stages of BC.

Material and Methods

This study was conducted at The Oncology Teaching Hospital / Baghdad Medical City from October/2018 to February/2019. Subjects enrolled in the study were 66 women that were recently diagnosed as having BC at different stages of the disease; and 22 apparently healthy women of comparable age to serve as control group. The age range of the subjects was 30-70 years. Specialist oncologist performed diagnosis and staging of BC according to Breast Cancer Staging, NCCN guidelines Version 4.2017 (29), a specialized pathologist using the WHO grading system, (30) performed the histological confirmation and grading.

BC patients at stage IV of the disease is characterized by metastasis to other organs, and those at stage 0 having either ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) of disease, were excluded from the study. Other excluded patients were those whom were already undergoing chemo-, radio-, or hormonal therapy; or those with autoimmune diseases or hemoglobinopathes, except iron deficiency anemia.
Subjects enrolled in the study were grouped as:
Group 1 including 22 BC women at stage I of the disease, Group 2 including 22 BC women at stage II of the disease, Group 3 including 22 BC women at stage III of the disease and Group 4 including 22 apparently healthy women serving as control group. Blood specimens were obtained from all participants. Serum levels of hepcidin and FPN were estimated quantitatively by sandwich type of enzyme linked immune-sorbent assay (ELISA), using kits purchased by R&D® (USA) for hepcidin and MyBioSource® (USA) for ferroportin. Measurements of total white blood cell count and platelet cell count were performed utilizing whole blood samples based on DynaHelix Flow technology. Estimation of blood hemoglobin was performed using colorimetric surfactant method.

Statistical analysis
Analysis of data was carried out using the available statistical package of SPSS-23 (Statistical Packages for Social Sciences- version 23). Data were presented in simple measures of mean, standard error, and range. Student t-test was used for testing the significant difference between two groups, whereas ANOVA among more than two groups by LSD post hoc multiple comparisons of data. Person’s correlation was calculated for studied quantitative variables. Statistical significance was considered whenever the P value was less than 0.05.

Results
Age range for group 1 was 32-67 years (51±2.3), for group 2 was 34-68 years, (47.63±1.87), and for group 3 was 32-65 year (45.5±1.75), While age range for control group was 31-60 years (44.3±1.5).
Table-1 summarized the descriptive date of BC patients and healthy control regarding age, body weight, height, and body mass index (BMI). There was no significant difference between total patients group and healthy control group regarding age, body weight, and height (P value 0.064,0.502,0.064 respectively) and significant difference regarding BMI (P value 0.041).

Table1. Descriptive Data of Total Patients and Control Groups

| Parameter          | BC Patients (n=66) | Healthy control (n=22) | P value |
|--------------------|--------------------|------------------------|---------|
| Age (years)        | 47.9±1.14          | 44.3±1.5               | 0.064   |
| Body weight (Kg)   | 74.07±1.15         | 72.04±2.7              | 0.502   |
| Height (cm)        | 159.8±0.81         | 163.04±2.05            | 0.064   |
| BMI (kg/m²)        | 28.8±0.3           | 26.96±0.82             | 0.041*  |

Data are expressed as mean± SE , BC: breast cancer, BMI: body mass index,* significant difference from control group (p˂0.05)

Table2. Descriptive data of studied groups.

| Parameter          | Group 1          | Group 2          | Group 3          | Group 4          |
|--------------------|-----------------|-----------------|-----------------|-----------------|
| Age (years)        | 51.5±2.3        | 46.2±1.66       | 45.9±1.79       | 44.3±1.5        |
| Body weight (Kg)   | 73.3±1.76       | 72.4±1.96       | 76.4±2.24       | 72.04±2.75      |
| Height (cm)        | 160.1±1.42      | 157.9±1.46      | 161.6±1.26      | 163.04±2.05     |
| BMI (kg/m²)        | 28.4±0.45       | 28.9±0.41       | 29.1±0.7        | 26.9±0.82       |

Data are expressed as mean± SE , BMI: body mass index

Data of Table-3 describe the differences between patients and control groups regarding family history, a number of smoker subjects, presence of diabetes mellitus, presence of hypertension. Sixteen of BC patients were presented with one or more first degree relative with BC in contrast to two of female control, all healthy control females were selected as none of them having diabetes mellitus nor hypertension and all of them were nonsmoker, while five of BC patients were diabetic and eight of them were hypertensive.

Table 3. Medical history of studied groups

| Parameter | BC patients n=66 | Healthy control n=22 |
|-----------|------------------|-----------------------|
| Family history | 16 | 2 |
| Smoker ** | 2 | None |
| DM | 5 | None |
| Hypertension*** | 8 | None |

BC: breast cancer, n=number, DM: diabetes mellitus,
Table 4 describes the differences among studied groups of patients regarding hormonal receptors state [estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 receptor (Her-2)], and histological classification of BC as invasive ductal carcinoma (IDC) was the predominant type followed by ductal carcinoma in situ (DCIS) with IDC , then invasive lobular carcinoma (ILC) with IDC and finally ILC .

Table 4. Basic criteria of studied patients in different stages of breast cancer

| Parameter | Stage I (n=22) | Stage II (n=22) | Stage III (n=22) | Total (n=66) |
|-----------|----------------|----------------|----------------|-------------|
| ER positive | 10 45.4 | 16 72.7 | 17 77.2 | 43 65.1 |
| PR positive | 12 54.5 | 16 72.7 | 16 72.7 | 44 66.6 |
| Her-2 positive | 9 40.9 | 10 45.4 | 9 40.9 | 28 42.4 |
| IDC | 16 72.7 | 15 68.1 | 14 63.6 | 45 68.1 |
| DCIS&IDC | 5 22.7 | 6 27.2 | 4 18.1 | 15 22.7 |
| ILC | 0 0 | 1 4.5 | 0 0 | 1 1.5 |
| ILC&IDC | 1 4.5 | 0 0 | 4 18.1 | 5 7.2 |

ER: estrogen receptor, PR : progesterone receptor, Her-2:human epidermal growth factor receptor, IDC :invasive ductal carcinoma, DCIS: ductal carcinoma in situ, ILC :invasive lobular carcinoma.

As presented in Table-5, there were significant elevations in serum hepcidin level, blood WBC count and blood platelet count of total BC patients as compared to control group, while there was significant decrease in blood hemoglobin level of total patients as compared to control and no significant difference between the groups regarding a serum ferroportin level.

Table 5. Blood and serum levels of the studied parameters among total patients and control groups

| Parameter | Total patients (n 66) | Control group (n 22) | P value |
|-----------|----------------------|---------------------|---------|
| S. hepcidin pg/ml | 499.09±16.4 | 179.4±19.8 | 0.000* |
| S.ferroportin ng/ml | 0.794±0.11 | 1.37±0.28 | 0.07 |
| B.hemoglobin gm/dl | 12.1±0.16 | 12.7±0.13 | 0.009* |
| B.WBC count (^10^3/µL) | 8.73±0.28 | 6.06±0.23 | 0.000* |
| B. platelet count (^10^3/µL) | 301.8±12.4 | 233.3±9.16 | 0.000* |

Data are expressed as mean ±SE, WBC: white blood cell ,B: blood ,S: serum

Table 6. Blood and serum levels of the studied parameters among the different study groups

| Parameter | Group 1 (n=22) | Group 2 (n=22) | Group 3 (n=22) | Group 4 (control) (n=22) | P value |
|-----------|----------------|----------------|----------------|-------------------------|---------|
| S. hepcidin pg/ml | 437.2± 26.4 | 501.4± 31.8 | 558.5± 21.3 | 179.4± 19.8 | 0.000* |
| S.ferroportin ng/ml | 0.589± 0.107 | 1.06± 0.31 | 0.733 ± 0.102 | 1.37± 0.28 | 0.07 |
| B.hemoglobin gm/dl | 12.2± 0.28 | 12.4± 0.37 | 11.9± 0.18 | 12.7± 0.13 | 0.17 |
| B. WBC count (^10^3/µL) | 7.39± 0.28 | 8.93± 0.48 | 9.86± 0.52 | 6.06± 0.23 | 0.000* |
| B. platelet count(^10^3/µL) | 282.2± 20.09 | 313.9± 19.3 | 309.2±25.3 | 233.3±9.16 | 0.016* |

Data are expressed as mean ±SE, WBC: white blood cell , B: blood ,S: serum

Figure-1 illustrates that serum hepcidin levels of patient groups are significantly higher than that of controls through different stages from I-III. Hepcidin levels tends to increase as the disease progresses; as presented by significantly higher levels in stage III compared to that in stage I.

Serum levels of FPN of stage I and III were significantly lower than that of control group with no significant difference between patient groups (Figure-2). Blood hemoglobin levels of stage III was significantly lower than that of control group with no significant difference between patients groups (Figure-3).
Correlation studies were done between all studied parameters among all groups including total patients, group 1, group 2, group 3, and group 4 and the significant results (that indicated positive or negative correlation) are tabulated in table-5. Serum hepcidin levels were significantly correlated with serum FPN levels in BC patients (total patient r=-0.407, stage II r=-0.678, stage III r=-0.433).

More advanced stages of BC (stage III) were presented with more significant correlation between FPN levels and blood platelet count (r=-0.438).

**Table 5.** Correlation study among studied groups

| x-axis   | y-axis          | r-value | P value | Group       |
|---------|----------------|---------|---------|-------------|
| S.hepcidin | S.ferroportin | -0.678  | 0.001   | Stage II    |
| S.hepcidin | S.ferroportin | -0.433  | 0.044   | Stage III   |
| S.hepcidin | S.ferroportin | -0.407  | 0.001   | Total patient|
| S.ferroportin | B.Platelet    | -0.438  | 0.041   | Stage III   |

S: serum, B: blood

**Discussion**

Globally, more than 95% of BCs diagnosed as adenocarcinomas (35), while IDC is the most common form of invasive breast cancer (accounting for 55% of incidence upon diagnosis) (36), and ILC constitutes only 5%–15% of invasive breast carcinoma (37). The results of this study agree with these results, as 68.1% of the patients having IDC, and only 1.5% of patients having ILC as mentioned in Table-2.

The important role of iron in DNA synthesis could lead to cell cycle arrest after iron depletion, (38) whereas chronic sub toxic levels feeding of iron to cancer cells transform them into a more aggressive phenotype which is prone to metastasis (39). Hepcidin induces FPN degradation, thus, interfering with iron efflux and cause iron sequestration in tumor cells. Moreover, hepcidin blocks iron export from cells such as macrophages and enterocytes (40). Serum levels of hepcidin are strictly controlled by different stimuli; iron status is the prime controller of hepcidin expression under basal conditions (41); yet, other factors can also control liver hepcidin expression, such as hormones, growth factors and heparins (42-44).

In this study, serum levels of hepcidin in all patients groups are significantly higher than that of the control group and the elevation was coordinated with the stage of the disease (P value 0.000, 0.000, 0.000 respectively) with significant elevation of stage III as compared to stage I (P value 0.001), while there was no significant difference between levels of stage I &II, stage II&III (P value 0.076
.115 respectively). While, serum FPN levels are significantly lower in patients with stage I and III than in the control group (P value 0.015 , 0.047 respectively). Serum FPN levels in patients with stage II was also lower than that of the control group but the difference was statistically non-significant (P value 0.325), and there were no significant differences between stages I&II and stages I&III and stages II&III (P value 0.142 , 0.65 , 0.307 respectively).

Similar findings were reported in previous studies. Orlandi et al (45) reported that patients with BC and benign breast lesions had significantly higher hepcidin levels than healthy control group. Similarly, Ciniselli et al (46) found that when compared with patients with benign breast diseases, patients with BC had significantly higher hepcidin levels. Also BC patients were reported to have higher serum hepcidin that is associated with lower levels of FPN when compared to healthy controls (45,47).

Patients with stage III showed significantly lower blood hemoglobin levels compared to that of the control group (P value 0.032) and non-significant decrease of stage I and stage II as compared to control group (P value 0.138 , 0.325 respectively) , and there were non-significant differences among patients groups (stages I&II , stages I&III, and stages II&III ) (P value 0.613 , 0.498 , 0.238 respectively) . These changes occur in accordance with the high hepcidin and low FPN levels. Twelve out of twenty two of BC patients at stage III have iron deficiency anemia at time of BC diagnosis. The number of anemic BC patients at stage I and stage II was much lower than that of patients at advance stage (stage III) (4/22 and 5/22) respectively; these findings point the important role of hepcidin in iron metabolism.

Hepcidin overexpression is not only associated with various hematological malignancies and some solid organs tumors such as breast, prostate cancers, but it also participate in the development of anemia in those patients (10,45,48).

In this study, there was a steady increase in TWBCC throughout disease stages , and there were significant elevations in all patients groups (stage I, II, and III) as compared to control group (P value 0.022 , 0.000 , 0.000 respectively) , even though the increase is still within normal range of blood WBC count [4-10(10^3/µl)] (19). There were significant elevations of stage II and III than that of stage I (P value 0.008 , 0.000 respectively) , and no-significant elevation of stage III than that of stage II (P value 0.103). Elevated WBC count has been shown to be associated with increased risks of the lung (19), gastric (22), and colorectal (23) cancers.

leukocytosis is associated with thrombocytosis which is negative prognostic indicator in patients with cancer (50,51). Thrombocytosis is associated with a poor cancer prognosis, suggesting a potential role for platelets in the pathogenesis of the disease (28).

In this study, platelet count of all patients group still within normal values. There were significant negative correlations between serum hepcidin levels and serum ferroportin levels of total patients, stage II patients group and stage III patient group, and these results may be related to negative regulatory role of hepcidin on FPN by induction of the later degradation (8,9) as these groups showed significant elevation of serum hepcidin level with decrease in FPN levels as compared to control. Also previous studies reported elevation of serum hepcidin in association with decreased FPN levels as compared to healthy control (45,52).

Conclusion
Hepcidin, ferroportin and hematological markers including hemoglobin, WBC count and platelets count are altered in women with BC compared to healthy control. The changes occur mostly in accordance with disease stage. Larger scale study testing validity of these markers in diagnosis and staging of BC is recommended.

Acknowledgements
I would like to thank all employees in The Oncology Teaching Hospital, doctors, nurses, lab staff and finally all the breast cancer patients and peoples for helping me to achieve this work.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocaic estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018; 68:394-424.
2. Tavassoli FA, Devilee P. WHO Classification of Tumors: Pathology and genetics of tumors of the breast and female genital organs. 3rd edition. Lyon, France. IARC press, 2003.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917):860-7.
4. DeNardo DG, Coussens LM. Inflammation and breast cancer: Balancing immune response-Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007; 9: 212.
5. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer. 2006; 6(2):130-40.
6. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhauser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27(21):3437-44.
7. Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P. Breast cancer statistics and
markers. J Cancer Res Ther. 2014;10(3):506-11.
8. Ward D, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta. 2012; 1823(9): 1426-33.
9. Camaschella C, Silvestri L. Molecular mechanisms regulating hepcidin revealed by hepcidin disorders. Scientific World Journal. 2011; 11:1357-66.
10. Nicolae CD, Coman OA, Ene C, Nicolae I, Fulga I. Hepcidin in neoplastic disease. J Med Life. 2013; 6:355-60.
11. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: From discovery to differential diagnosis. Haematologica. 2008; 93: 90-7.
12. Cizmeci MN, Kara S, Kanburuglu MK, Simavli S, Duvan CI, Tatli MM. Detection of cord blood hepcidin levels as a biomarker for early-onset neonatal sepsis. Med Hypotheses. 2014;82:310-2.
13. Dudkowiak R, Neubauer K, Poniewierka E. Hepcidin and its role in inflammatory bowel disease. Adv Clin Exp Med. 2013; 22: 585-91.
14. Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm. 2007; 64:S5-13.
15. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18: 555-9.
16. Iamy PJ, Durigova A, Jacot W. Iron homeostasis and anemia markers in early breast cancer .Iron and breast cancer .Clinic Chim Acta. 2014 ;434:34-40.
17. Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol. 2002; 169:2204-9.
18. Wen J, Ye F, Huang X, Li S, Yang L, Xiao X, & Xie X. Prognostic Significance of Preoperative Circulating Monocyte Count in Patients with Breast Cancer: Based on a Large Cohort Study. Medicine.2015; 94(49): e2266.
19. Koh Y W, Lee H J, Ahn J H, Lee J W, & Gong G. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumor Biol. 2014; 35(10): 9823-30.
20. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, Binda E, Jungner I. Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiology Biomarkers & Prevention. 2011; 20(3): 428-37.
21. Cook E. Total white blood cell count, Absolute neutrophil count, absolute lymphocyte count, neutrophil-to-lymphocyte ratio and the risk of breast cancer: the NHANES I epidemiologic follow-up study. Cancer Research journal 2016; 4(3):52-7.
22. Iida, M, Ikeda F, Ninomiya T, Yonemoto K, Doi Y, Hata H, & Kiyohara Y. White Blood Cell Count and Risk of Gastric Cancer Incidence in a General Japanese Population The Hisayama Study. Am J Epidemiol. 2012; 175(6): 504-5.
23. Margolis K. L., Rodabough R. J., Thomson, C. A., Lopez, A. M., & McTiernan, A. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med.2007; 167(17):1837-44.
24. Gay LJ, Felding-Habermann B. Contribution of platelets to tumor metastasis. Nat Rev Cancer. 2011; 11: 123-34.
25. Li N. Platelets in cancer metastasis: to help the ‘villain’ to do evil. Int J Cancer. 2016; 138: 2078-87.
26. Lal I, Dittus K, Holmes CE. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res. 2013; 15(4):207.
27. Taucher S, Salat A, Gnart M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R. Austrian Breast and Colorectal Cancer Study Group .Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003 ; 89:1098-106.
28. Sierko E, Wojtukiewicz M Z .Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004; 30:95-108.
29. Gradishar WJ, Anderson BO, Balassanian R, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. NCCN guidelines Version 4.2017, Breast Cancer Staging. J Natl Compr Canc Netw 2018; 16:310-20.
30. Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO Classification of Tumors of the Breast. 4th ed. Lyon :IARC , No 4; 2012.( bookorders@who.int).
31. Gan SD .Patel KR .Enzyme immunoassay and enzyme -linked immunosorbent assay . J Invest Dermatol. 2013;133(9):e12.
32. 32.CLSI .Validation and Quality Assurance of Automated Hematology Analyzers .Approved Standard, 2nd ed.H26-A2.Wayne ,PA: Clinical and Laboratory Standard Institute ;2010.
33. ICSH Expert Panel on Cytometry and ISLH Task Force on Platelet Counting. Platelet Counting by the RBC/Platelet Ratio Method .A
Serum hepcidin and ferroportin in breast cancer

Reference Method . Am J Clin Pathol 2001;115:460-64.

34. CLSI . Reference and Selected Procedures for the Quantitative Determination of Hemoglobin in Blood ; Approved standard-3rd ed.H15-A3. Wayne , USA : Clinical and Laboratory Standards Institute . 2000.

35. Kumar V, Abbas AK , Fausto N .Aster J. Pathologic Basis of Disease . 8th ed.Philadelphia: Elsevier Saunders; c 2010.Robbins and Cotran.

36. Eheman CR, Shaw KM, Ryerson AB, et al. The changing incidence of in situ and invasive ductal and lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1763-9.

37. Mahotra G, Zhao X ,Band H. Histological, molecular and functional subtypes of breast cancers .Cancer Biol  Ther .2010;10(10):955-60.

38. Terada N, Or R, Szepesi A, Lucas JJ, Gelfand EW. Definition of the roles for iron and essential fatty acids in cell cycle progression of normal human T lymphocytes.Exp Cell Res 1993; 204: 260 –67.

39. Chanvorachote P, Luanpitpong S. Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells. Am J Physiol 2016; 310: C728 –C739.

40. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012; 1823: 1434 –43.

41. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L , Knutson MD, Pietrangelo A, Vukicevic S, Lin HY, Babitt JL. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet . 2009; 41: 482 –87

42. Lehtihet M, Bonde Y, Beckman L, Berinder K, Hovybe C, Rudling M, Sloan JH3, Konrad RJ3, Angelin B1 . Circulating hepcidin-25 is reduced by endogenous estrogen in humans. PLOS ONE 2016; 11: e0148802.

43. Goodnough JB, Ramos E, Nemeth E, Ganz T. Inhibition of hepcidin transcription by growth factors. Hepatology .2012; 56: 291 -99.

44. Poli M,Girelli D, Campostrini N,Maccarinelli F, Finazzi D, Luscieti S , Nai A, Arosio P. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood .2011; 117: 997 –1004.

45. Orlandi R, De Bortoli M, Ciniselli CM , Vaghi E, Caccia D, Garrisì V, Pizzamiglio S, Veneroni S, Bonini C, Agresti R, Daidone MG, Morelli D, Camaschella C, Verderio P, Bongarzone I. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol 2014; 25:352-57.

46. Ciniselli CM ,De Bortoli M, Taverna E, Pla Ciniselli CM, De Bortoli M, Taverna E, Varinelli L. , Pizzamiglio S, Veneroni S, Bonini C, Orlandi R, Verderio P, Bongarzone I. Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone . Expert Rev Proteomics .2015  ; 12: 695-701.

47. Pogribny IP. Ferroportin and hepcidin: A new hope in diagnosis, prognosis, and therapy for breast cancer. Breast Cancer Res 2010; 12: 314.

48. Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gutley JL, Miller JL. Hepcidin, anaemia, and prostate cancer. BJU Int 2011; 107:678 – 9.

49. Dacie and Lewis Practical Hematology .Chapter 2,Reference ranges and normal values .In: Dacie and Lewis Practical Hematology .12th ed .Bain BJ ,Bates I,Laflan MA ,Lewis M (eds) .London ;Elsevier .2017.

50. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2008; 7:613-5.

51. Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ, Negrier S, Andresen SW, Bukowski RM. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006; 107: 1793-800.

52. Pogribny IP. Ferroportin and hepcidin: A new hope in diagnosis, prognosis, and therapy for breast cancer. Breast Cancer Res 2010; 12:314.